Movement Disorders Enrollment Form



Fax Referral To: 1-800-323-2445 Email Referral To: Customer.ServiceFax@CVSHealth.com

Phone: 1-866-215-9855

PATIENT IN	FORMATION (Complete or incl	ude demographic sheet)						
Patient Name:		DOB:	·	Gender: 🗌	Male 🗌 Female			
	dress:City, State, ZIP Code:							
Note: Carrier charge: text messages from contact via text or en	Methods: Phone (to primary # provings may apply. By providing the phone number CVS Specialty® about your prescription(s), anail, Specialty Pharmacy will attempt to contain	er(s) and email address above, account, and health care. Standatact by phone.	you are consentin lard data rates ap	g to receive automa oly. Message freque	ted calls, emails and/or ency varies. If unable to			
	Last Four of SSN: Primary Language:egiver/Legal Guardian Name (Last, First): Relationship to patient :							
Parent/Caregiver/								
2 PRESCRIBE	R INFORMATION							
Drosoribor's Name	o:	State License #	. .					
NDI #·	DEA #: Group	State Licerise #	·					
Address:	BLA # Group	Group or Hospital: City, State, ZIP Code: Contact's Phone: Contact Person: Contact Phone: Contact Person:						
Phone:	Fax	Contact Person:		Contact's Phon	e:			
4 DIAGNOSIS	E INFORMATION Please fax cor S AND CLINICAL INFORMAT	ΓΙΟΝ						
Diagnosis (ICD- ☐ G24.01 Tardive ☐ G10 Huntingtor ☐ G72.3 Periodic	10): Dyskinesia (TD) n's Chorea (HD)							
Patient Clinical	Information:	Height:i						

Movement Disorders Enrollment Form

Please Complete Patient and Prescriber information							
Patient Name:	ne:Patient DOB:Patient Phone:						
Prescriber Name:	Prescriber Phone:						
5 PRESCRIPTION INFORMATION							
MEDICATION	STRENGTH		DOSE & DIRECTIONS	QUANTITY/REFILLS			
Austedo Initial Titration Rx-TD	☐ 6 mg ☐ 9 mg ☐ 12 mg	Administer 9 mg l	by mouth twice a day during Week 1 by mouth twice a day during Week 2 by mouth twice a day during Week 3 by mouth twice a day during Week 4	Quantity: 30-day supply Refills: None			
Austedo Maintenance Rx-TD	6 mg 9 mg 12 mg	Administer two 12	mg tablets twice a day by mouth (48 mg/day)	Quantity: Refills:			
Austedo Initial Titration RX-HD	☐ 6 mg ☐ 9 mg ☐ 12 mg	Administer 6 mg l Administer 9 mg l Administer 12 mg	by mouth once a day during Week 1 by mouth twice a day during Week 2 by mouth twice a day during week 3 by mouth twice a day during Week 4	Quantity: 30-day supply Refills: None			
Austedo Maintenance Rx-HD	6 mg 9 mg 12 mg	mg/day)	2 mg tablets twice a day by mouth (48	Quantity: Refills:			
☐ Dichlorphenamide	☐ 50 mg	Take tablet(s)) by mouth daily.	Quantity: Refills:			
☐ Ingrezza Initial Rx	☐ 40 mg ☐ 80 mg	mouth once daily x 2	g by mouth once daily x 7 days then 80 mg by 3 days.	Quantity: Refills: None			
☐ Ingrezza Maintenance Rx	☐ 80 mg	Administer 80 mg by		Quantity: 30 Refills:			
☐ Ingrezza Maintenance Rx	☐ 40 mg	Administer 40 mg by	mouth once a day	Quantity: 30 Refills:			
☐ Ingrezza Maintenance Rx	☐ 60 mg	Administer 60 mg by	mouth once a day	Quantity: 30 Refills:			
☐ Ingrezza Maintenance Rx	Other	Other					
Patient is interested in patient support programs	STAMPS	SIGNATURE NOT ALLOWED	Ancillary supplies and kits provided as	needed for administration			
6 PRESCRIBER SIGNATURE REQUIRED (STAMP SIGNATURE NOT ALLOWED)							
"Dispense As Written" / Brand Medically Nece DAW / May Not Substitute Prescriber's Signature:	ssary / Do Not Subst	itute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible Prescriber's Signature:				
CA, MA, NC & PR: Interchange is mandated unless Prescriber writes the words "No Substitution" ATTN: New York and Iowa providers, please submit electronic prescription							

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments. Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.